Organised by SHC
The Science of HBV Cure Meeting 2026 LIVE
For Scientists, Clinician Scientists and
Pharmacists and Industry Experts
4 – 5 September 2026
9.00am – 5.30pm (SGT)
The Science of HBV Cure Meeting 2026 LIVE
Register for Live Meeting
You will automatically be enrolled for SHC 2026 Online upon registration of the Science of HBV Cure Meeting 2026
Who Should Attend?
The Science of HBV Cure Meeting is important for patients, doctors, scientists and pharmaceutical companies seeking to understand Hepatitis B and its new treatments. In particular, Hepatitis B cure is becoming a reality with new drugs tested in phase 3 clinical trials.
Additionally, Hepatitis D is also emerging as a disease for which therapy is rapidly evolving. The Science of HBV Cure Meeting will also discuss the emerging treatments for HDV.
The Science of HBV Cure Meeting 2026 LIVE Scientific Programme
Full Programme currently in preparation
| 4 September 9.00am to 17.30pm SGT |
|
|---|---|
| The Science of Functional Cure | 9.00am To 12.30pm |
| New Antiviral Therapies | 14.00pm To 17.30pm |
| 5 September 9.00am – 17.30pm SGT |
|
|---|---|
| Immune Modulation in CHB | 9.00am To 12.30pm |
| The Future of HBV Functional Cure | 14.00pm To 17.30pm |
September, 2026
4
| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | 8.30 – 8.40 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: |
|
| HBV Cure: update on definitions from the Asian Consensus Conference | 8.40 – 9.00 |
| Challenges to achieve functional cure | 9.00 – 9.20 |
| Landscape of functional cure 2026 | 9.20 – 9.40 |
| Q&A | 9.40 – 9.50 |
| Poster Presentation | 9.50 – 10.30 |
| Morning Tea | 10.30 – 10.50 |
| Virological Insights into functional cure Moderators: |
|
| Virological Cure and complete cure: achievable or imaginary? – |
10.50 – 11.10 |
| integrated HBV: whats important? Burden, integration site or clonal expansion – |
11.10 – 11.30 |
| Q&A | 11.30 – 11.50 |
| Free Paper (15 minutes presentation and 5 minutes Q&A) | 11.50 – 12.10 |
| Lunch | 12.10 – 13.30 |
| Intrahepatic microenvironment Moderator: |
|
| Spatial transcriptomics: state of the art | 13.30 – 13.50 |
| Intrahepatic immune correlates of functional cure | 13.50 – 14.10 |
| Q&A | 14.10 – 14.30 |
| Free Paper Presentations | |
| Free paper (15 minutes presentation and 5 minutes Q&A) | 14.30 – 14.50 |
| Animal Models Moderator: |
|
| Benefits and limitations of animal models for immune modulators for FC – (15 minutes presentation and 5 minutes Q&A) |
14.50 – 15.15 |
| Free paper (15 minutes presentation and 5 minutes Q&A) – |
15.15 – 15.35 |
| Tea Break | 15.35 – 16:00 |
| Strategies with existing agents Moderator: |
|
| Stopping nucleoside analogues: is there still a role in FC? – |
16.00 – 16:20 |
| Peginterferon: never say die – |
16:20 – 16:40 |
| Q&A | 16:40 – 17:00 |
| Biomarkers Moderator: Prof. Seng Gee Lim |
|
| The role of ultrasensitive HBsAg in clinical trials of novel therapies – |
17:00 – 17:20 |
| Biomarkers that corelate with cccDNA – |
17:20 – 17:40 |
| Q&A | 17:40 – 18:00 |
| Closing remarks | 18:00 – 18.05 |
| End of day 1 | |
September, 2026
5
| Programme | Time (SGT) |
|---|---|
| RNA interference Moderators: |
|
| Anti-sense oligonucleotides: are they immune modulators? (20 minutes presentation and 10 minutes Q&A) – |
8.30 – 9.00 |
| Free paper (15 minutes presentation and 5 minutes Q&A) – |
9.00 – 9.20 |
| Invited Pharma Presentations Moderators: |
|
| Bepirovirsen phase 3 – |
9.20 – 9.35 |
| AHB-137, update – |
9.35 – 9.50 |
| siRNA+Neutralizing antibody – |
9.50 – 10.05 |
| Q&A | 10.05 – 10.25 |
| Tea Break | 10.25 – 10.45 |
| Delta Cure Moderator: |
|
| Delta Cure update – |
10.45 – 11.05 |
| Novel therapeutics for Delta Cure – |
11.05 – 11.20 |
| Q&A | 11.20 – 11.35 |
| Immunology Chair and moderator: |
|
| Therapeutic vaccines: are they fulfilling their promise? – |
11.35 – 11.55 |
| Antibody therapeutics in the quest for FC – |
11.55 – 12.10 |
| Q&A | 12.10 – 12.30 |
| Lunch | 12.30 – 14.00 |
| Invited pharma Presentations Moderator: |
|
| Ascletis – |
14.00 – 14.15 |
| Brii – |
14.15 – 14.30 |
| Virion therapeutics – |
14.30 – 14.45 |
| Q&A | 14.45 – 15.00 |
| Tea Break | 15.00 – 15.30 |
| Gene Therapy Moderators: |
|
| :Early clinical results of gene/epigenetic editing – |
15.30 – 15.50 |
| The safety of gene editing: What to measure and how long? – |
15.50 – 16.10 |
| Q&A | 16.10 – 16:25 |
| Combination Therapy Forum Moderators: |
|
| Immunotherapy and antiviral therapy forum – |
16.25 – 17.25 |
| Closing remarks from Chairman | 17:25 – 17:30 |
Call for Abstracts
Submission Deadline: 7 July 2026
We invite all interested parties to present their research papers. (abstracts of Case Studies will not be accepted) Click on below Abstracts and Posters for further information.
Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on Abstract & Poster Gallery in our website and in the Poster Hall. Presenters of oral presentations of accepted Abstracts as Free Papers will receive USD800 and a registration fee refund to help defray the cost of travel and accommodation here in Singapore. This payment will be made after the presentation.
Only abstracts of research papers will be accepted. Abstracts of Case Studies will not be accepted.